Eton Pharmaceuticals Inc. (ETON) Misses Q4 EPS by 5c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of ($0.09), $0.05 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.7 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• Snowflake soars 20% on earnings beat and raised guidance